The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,041,816 in first-year total cost, median $677,487.
Most frequent study sections
- Special Emphasis Panel[ZDA1 PXN-F (01)]3
Most frequent institutions
- JOHNS HOPKINS UNIVERSITY1
- ROSWELL PARK CANCER INSTITUTE CORP1
- UNIVERSITY OF CALIFORNIA LOS ANGELES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Assessing pharmacokinetic and pharmacodynamic variability of Δ9-tetrahydrocannabinol delivered from vaping products with and without concurrent use of nicotine1R01DA057228-01 | GONIEWICZ, MACIEJ LUKASZSMITH, DANIELLE | ROSWELL PARK CANCER INSTITUTE CORP, NY | $706,151 | ZDA1 |
| 2022 | Age-and sex-dependent pharmacodynamics and pharmacokinetics of oral and smoked delta-9-THC1R01DA057252-01 | COOPER, ZIVA D | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $677,487 | ZDA1 |
| 2022 | The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Delta-9THC-Infused Cannabis Edibles1R01DA057201-01 | SPINDLE, TORY RICHARD | JOHNS HOPKINS UNIVERSITY, MD | $658,178 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.